Blockade of the renin-angiotensin system (RAS) with angiotensin-converting enzyme inhibitors (ACEi) or angiotensin-receptor blockers (ARBs) is a critical component of chronic kidney disease (CKD) management. This evidence concerns the gene ACE and chronic kidney disease.